Impact News +++ Ad-hoc News: Gerresheimer AG (EQS) +++ GERRESHEIMER Aktie -4,16%

APELLIS Aktie

>APELLIS Aktienkurs

16.878 EUR +1.2% (Tradegate)

Ask: 16.946 EUR / 900 Stück

Bid: 16.846 EUR / 900 Stück

Tagesumsatz: 207 Stück

Realtime Kurs von 8 bis 22 Uhr!

APELLIS Aktie über LYNX handeln

Intraday

1 Jahr

>APELLIS Performance

1 Woche: +8,8%

1 Monat: +1,8%

3 Monate: -1,6%

6 Monate: -42,4%

1 Jahr: -54,8%

laufendes Jahr: -46,7%

>APELLIS Aktie

Name:

APELLIS PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US03753U1060 / A2JAAW

Symbol/ Ticker:

1JK (Frankfurt) / APLS (NASDAQ)

Kürzel:

FRA:1JK, ETR:1JK, 1JK:GR, NASDAQ:APLS

Index:

Webseite:

https://www.apellis.com/

Marktkapitalisierung:

2120 Mio. EUR

Umsatz:

680.83 Mio. EUR

EBITDA:

-161.84 Mio. EUR

Gewinn je Aktie:

-1.378 EUR

Schulden:

412.05 Mio. EUR

Liquide Mittel:

317.97 Mio. EUR

Umsatz-/ Gewinnwachstum:

-3.2% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

2.95 / 14.07 / -

Gewinnm./ Eigenkapitalr.:

-28.83% / -103.82%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 93.850 USD.

Suchwörter:

APELLIS

Letzte Datenerhebung:

16.07.25

>APELLIS Eigentümer

Aktien: 125.68 Mio. St.

f.h. Aktien: 77.46 Mio. St.

Insider Eigner: 13.76%

Instit. Eigner: 104.56%

Leerverk. Aktien: 21.02%

>APELLIS Peer Group

ALNYLAM

ANI PHARMA

BIOMARIN

EDWARDS LIFESCIENCES

EXACT SCIENCES

INCYTE

IONIS

LANTHEUS

UNIVERSAL HEALTH SERVICES

ZOETIS

>APELLIS Chart & Kurs - NASDAQ

>APELLIS News

15.07.25 - 13:03

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting (GlobeNewswire EN)

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, California. These data further demonstrate the robust efficacy and well-documented safety profile of SYFOVRE® (pegcetacoplan injection) for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)....

02.07.25 - 18:15	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks)
	APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects....

01.07.25 - 15:06	Apellis signs royalty purchase deal with Sobi for Aspaveli (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.07.25 - 13:45	Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) (PR Newswire)
	STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275......

01.07.25 - 13:03

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) (GlobeNewswire EN)

WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300 million in exchange for 90% of Apellis' future ex-U.S. royalties for Aspaveli® (systemic pegcetacoplan). Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI®....

18.06.25 - 16:01	Insiderhandel: General Counsel verkauft Aktien von Apellis Pharmaceuticals im Wert von 93850 USD (Insiderkauf)
	Watson, David O. - Vorstand - Tag der Transaktion: 2025-06-16...

06.06.25 - 17:45	Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.06.25 - 15:42	Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases (PR Newswire)
	STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex......

06.06.25 - 15:18

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN (GlobeNewswire EN)

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress....

09.05.25 - 15:01	Apellis Pharmaceuticals downgraded by Raymond James due to ′added uncertainty′ (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.25 - 18:15	Apellis′ Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
	APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates....

08.05.25 - 00:36	Why Apellis Pharmaceuticals Wilted on Wednesday (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 16:30	Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
	The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....

07.05.25 - 13:18	Apellis Pharmaceuticals GAAP EPS of -$0.74 misses by $0.39, revenue of $166.8M misses by $28.08M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 13:03	Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results (GlobeNewswire EN)
	WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights....

06.05.25 - 18:15	Apellis Pharmaceuticals Q1 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.04.25 - 13:03

Apellis Announces Craig Wheeler to Join the Board of Directors (GlobeNewswire EN)

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry....

02.04.25 - 16:45	APLS′ Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag (Zacks)
	The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway....

01.04.25 - 15:33	Apellis gets FDA Priority Review for its kidney disease treatment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.04.25 - 13:03

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN (GlobeNewswire EN)

WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases. The Prescription Drug User Fee Act (PDUFA) target action date is July 28, 2025....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Vollkommene Politik besteht darin, niemals das letzte Motiv zu enthüllen. - Benjamin Disraeli

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram